GLUE Overview

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is30.40 USD with a low forecast of 20.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Monte Rosa Therapeutics Inc revenue for the last quarter amounts to 12.77M USD, increased 38.54

Monte Rosa Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, increased 13.79

Monte Rosa Therapeutics Inc (GLUE) has 134 emplpoyees as of March 11 2026.

Today GLUE has the market capitalization of 1.32B USD.